Merck to Cut 17,500 Jobs by 2012
Merck & Co. (Whitehouse Station, NJ) has announced restructuring plans that include reducing its companywide workforce by 15% by the end of 2012.
Merck & Co. (Whitehouse Station, NJ) has announced restructuring plans that include reducing its companywide workforce by 15% by the end of 2012. Per the company’s 8-K filing with the US Securities and Exchange Commission, the company also will eliminate 2,500 currently vacant positions, which could mean a total of 17,500 layoffs.
Merck says it will achieve these reductions by eliminating duplicative positions in sales, administrative, and headquarters functions, and by consolidating manufacturing plants and research and development operations.
These layoffs are a part of the company’s ongoing cost reduction initiatives since Merck’s $41.1 billion acquisition of Schering-Plough last November. Merck expects this first phase of its restructuring program to yield annual savings in 2012 of approximately $2.6 to $3.0 billion.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
